Rectal cancer risk (9 studies) · adults (aged at least 18 years)
Highest showed no clear difference in rectal cancer risk (9 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.89 [0.75, 1.05]
356851 participants
Low
Lung cancer risk (17 studies) · adults (aged at least 18 years)
It is very uncertain whether highest changes lung cancer risk (17 studies) compared with lowest green tea exposure (very low certainty).
1 finding from 1 review
RR 0.88 [0.76, 1.02]
269565 participants
Very low
Breast cancer risk (14 studies) · adults (aged at least 18 years)
It is very uncertain whether highest changes breast cancer risk (14 studies) compared with lowest green tea exposure (very low certainty).
1 finding from 1 review
RR 0.88 [0.75, 1.02]
250822 participants
Very low
Gynaecological cancer risk (10 studies) · adults (aged at least 18 years)
Highest may leads to lower gynaecological cancer risk (10 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.69 [0.57, 0.83]
66738 participants
Low
Endometrial cancer risk (5 studies) · adults (aged at least 18 years)
Highest may leads to lower endometrial cancer risk (5 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.77 [0.65, 0.91]
60416 participants
Low
Gynaecological cancer incidence · adults (aged at least 18 years)
Green tea extract supplementation showed no clear difference in gynaecological cancer incidence compared with placebo (low certainty).
1 finding from 1 review
Ovarian cancer risk (5 studies) · adults (aged at least 18 years)
Highest may leads to lower ovarian cancer risk (5 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.64 [0.45, 0.9]
6322 participants
Low
Prostate cancer risk (13 studies) · adults (aged at least 18 years)
It is very uncertain whether highest changes prostate cancer risk (13 studies) compared with lowest green tea exposure (very low certainty).
1 finding from 1 review
RR 0.73 [0.56, 0.94]
127239 participants
Very low
Urinary tract cancer risk (7 studies) · adults (aged at least 18 years)
It is very uncertain whether highest changes urinary tract cancer risk (7 studies) compared with lowest green tea exposure (very low certainty).
1 finding from 1 review
RR 1.04 [0.79, 1.37]
156039 participants
Very low
Non‐melanoma skin cancer incidence · adults (aged at least 18 years)
Green tea extract supplementation showed no clear difference in non‐melanoma skin cancer incidence compared with placebo (low certainty).
1 finding from 1 review
Quality of life · adults (aged at least 18 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence: all cancers · adults (aged at least 18 years)
Highest showed no clear difference in any cancer incidence (3 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.83 [0.65, 1.07]
52479 participants
Low
Mortality: all cancers · adults (aged at least 18 years)
Highest showed no clear difference in any cancer mortality (8 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.99 [0.91, 1.07]
504366 participants
Low
Oral cancer risk · adults (aged at least 18 years)
Highest may leads to lower oral cancer risk (5 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.71
55977 participants
Low
Any gut cancer risk (7 studies) · adults (aged at least 18 years)
Highest showed no clear difference in any gut cancer risk (7 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.78 [0.59, 1.02]
70299 participants
Low
Cognitive and neurobehavioural outcomes · children (aged 0–2 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children (aged 0–6 years)
The review found no eligible studies for this question.
2 findings from 1 review
Blood lead levels (continuous)Blood lead level at end of duration Scale: 0–30 · children (aged 0–6 years)
2 findings from 1 review
Cognitive and neurobehavioural outcomes · children (aged 0–4 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children (aged 0–4 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found